Synapse
⌘+K
Sign In
Sign Up for Free
Synapse
Sign In
Sign Up for Free
Home
Communities
Explore
More
Language
English
English
Otsuka (Germany)
h-index: 20
Total citations: 1,222
Total papers: 75
Homepage:
http://otsuka-onpg.com/
Recent papers from Otsuka (Germany)
The regulatory landscape in tuberculosis integrated research platforms
European Respiratory Journal · 2026
Efficacy and safety of a 4-month quabodepistat, delamanid, and bedaquiline regimen for drug-susceptible pulmonary tuberculosis: a multicentre, open-label, randomised, proof-of-concept, non-inferiority, phase 2b/c trial
The Lancet Infectious Diseases · 2026
A Comprehensive Approach to Selection of Adverse Drug Reactions for a Drug with Conditional Marketing Authorisation in the European Union
Advances in Therapy · 2026
Inclusion of patient-centered, non-microbiological endpoints and biomarkers in tuberculosis drug trials
Frontiers in Antibiotics · 2025
15-year trends in efficacy and effectiveness of treatment outcomes in drug-resistant pulmonary TB
IJTLD OPEN · 2025
Five years of post-marketing liver safety data from the tolvaptan Risk Evaluation and Mitigation Strategy
Clinical Kidney Journal · 2025
Safety, pharmacokinetics, and early bactericidal activity of quabodepistat in combination with delamanid, bedaquiline, or both in adults with pulmonary tuberculosis: a randomised, active-controlled, open-label trial
The Lancet Infectious Diseases · 2024
Real-world data in lupus nephritis: results from a European survey on renal function testing and burden of disease progression
Current Medical Research and Opinion · 2024
Candidate anti-tuberculosis medicines and regimens under clinical evaluation
Clinical Microbiology and Infection · 2024
Real-life use of delamanid: results from the European post-authorisation safety study
Deleted Journal · 2024
Developing biomarker assays to accelerate tuberculosis drug development: defining target product profiles
The Lancet Microbe · 2024
Quabodepistat in combination with delamanid and bedaquiline in participants with drug-susceptible pulmonary tuberculosis: protocol for a multicenter, phase 2b/c, open-label, randomized, dose-finding trial to evaluate safety and efficacy
Trials · 2024
Safety Evaluation in Iterative Development of Wearable Patches for Aripiprazole Tablets With Sensor: Pooled Analysis of Clinical Trials
JMIR Formative Research · 2023
Exploring preferences of different modes of administration of hypomethylating agent treatments among patients with acute myeloid leukemia
Frontiers in Oncology · 2023
Determining the Delamanid Pharmacokinetics/Pharmacodynamics Susceptibility Breakpoint Using Monte Carlo Experiments
Antimicrobial Agents and Chemotherapy · 2023
Phase 3b Multicenter, Prospective, Open-label Trial to Evaluate the Effects of a Digital Medicine System on Inpatient Psychiatric Hospitalization Rates for Adults With Schizophrenia
The Journal of Clinical Psychiatry · 2022
Compassionate use of delamanid in adults and children for drug-resistant tuberculosis: 5-year update
European Respiratory Journal · 2020
Long-term safety and tolerability of delamanid-containing regimens in multidrug-resistant and extensively drug-resistant tuberculosis patients in a specialised treatment centre in Berlin, Germany
European Respiratory Journal · 2020
Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial
The Lancet Respiratory Medicine · 2019
Compassionate use of delamanid in combination with bedaquiline for the treatment of multidrug-resistant tuberculosis
European Respiratory Journal · 2018